Merck (MRK) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $317.54B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert Davis |
| IPO Date | 1978-01-13 | CAGR | 7.54% |
| Employees | 75,000 | Website | www.merck.com |
| Div. Yield | 2.61% | Payout Ratio | 262% |
| Buy Back Yield | 0.12% | Total Yield | 2.73% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $364.71B | P/E | 40.05 | Forward P/E | 13.39 | PEG | — |
| P/S | 4.78 | P/B | 7.61 | P/CF | 15.97 | P/FCF | 19.77 |
| Sales | $66.40B | Sales 1Y | 4.24% | Sales 3Y | 13.87% | Sales 5Y | 46.02% |
| EPS | $3.21 | EPS 1Y | -80.74% | EPS 3Y | 2.46% | EPS 5Y | -43.18% |
| Sales QoQ | 1.97% | EPS QoQ | -68.6% | Sales QoQ Avg | 1.37% | EPS QoQ Avg | -82.51% |
| Gross Margin | 75.38% | Operating Margin | 17.03% | Profit Margin | 4.78% | ROCE | 13.71% |
| ROA | 3% | ROE | 7% | Altman Z Score | 4.5 | Piotroski Score | 5 |
| Current Ratio | 1.32 | Quick Ratio | 1.1 | Cash Ratio | 0.25 | Op. CF Ratio | 0.19 |
| Debt/Equity | 1.29 | Debt/Assets | 0.49 | Lt Debt/Equity | 1.22 | Lt Debt/Cap. | 0.55 |
| Intrst Cov. | 15.32 | Inventory Turnover | 2.63 | Asset Turnover | 0.6 | Receivables Turnover | 5.28 |
| Enterprise Value | $364.71B | P/E Ratio | 40.05 |
| Forward P/E | 13.39 | PEG Ratio | — |
| P/S Ratio | 4.78 | P/B Ratio | 7.61 |
| P/CF Ratio | 15.97 | P/FCF Ratio | 19.77 |
| EPS | $3.21 | EPS Growth 1Y | -80.74% |
| EPS Growth 3Y | 2.46% | EPS Growth 5Y | -43.18% |
| Revenue Growth 1Y | 4.24% | Gross Margin | 0.75% |
| Operating Margin | 0.17% | Profit Margin | 0.05% |
| ROE | 0.07% | ROA | 0.03% |
| ROCE | 0.14% | Current Ratio | 1.32 |
| Quick Ratio | 1.1 | Cash Ratio | 0.25 |
| Debt/Equity | 1.29 | Interest Coverage | 15.32 |
| Altman Z Score | 4.5 | Piotroski Score | 5 |
Merck (MRK) valuation & financials
Merck (MRK) has a market capitalization of $317.54B and trades at a price-to-earnings ratio of 40.0. It operates in the Healthcare sector (Drug Manufacturers - General).
Merck's revenue grew +4.2% over the last year.
Merck's next earnings report is scheduled for October 29, 2026 before market open; analysts estimate EPS of $2.27. Check the earnings calendar to see all companies reporting this week.
Merck (MRK) — frequently asked questions
When does Merck (MRK) report earnings next?
Merck is expected to report earnings on October 29, 2026 before market open. Analysts estimate EPS of $2.27.
What is Merck's market cap?
Merck (MRK) has a market capitalization of $317.54B.
What is MRK's P/E ratio?
Merck trades at a price-to-earnings ratio of 40.0, with trailing twelve-month EPS of $3.21.
How fast is Merck growing?
Merck's revenue grew +4.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Novartis (NVS)